ALNY Alnylam Pharmaceuticals, Inc.
Stock · NasdaqGS · United States · Healthcare · US02043Q1076
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Alnylam Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
155.94 USD
-0.46%
52-week range
156.00 – 479.79
Dividend yield—
Market cap21.0B
NowoTrade score
69 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:10. Information, not advice.
Results
Next results
11 Feb 2027
in 96 days · 08:00 · estimate 2.33
Last results
16.26 vs 2.25 estimated
29 Oct 2026 · Beat +623.0%
Beat the estimate
8 of 12
3 missed · 1 in line
Average surprise
+106.8%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 08:00 | 2.33 | — | — | Upcoming |
| 29 Oct 2026 08:00 | 2.25 | 16.26 | +623.0% | Beat |
| 30 Jul 2026 08:00 | 2.14 | 1.84 | -14.2% | Miss |
| 30 Apr 2026 08:00 | 1.47 | 1.99 | +35.3% | Beat |
| 12 Feb 2026 08:00 | 1.50 | 1.25 | -16.5% | Miss |
| 30 Oct 2025 08:00 | 1.75 | 2.90 | +66.1% | Beat |
| 31 Jul 2025 08:00 | 0.15 | 0.32 | +119.6% | Beat |
| 01 May 2025 08:00 | -0.37 | -0.01 | +97.3% | Beat |
| 13 Feb 2025 08:00 | -0.14 | 0.06 | +142.5% | Beat |
| 31 Oct 2024 08:00 | -0.39 | -0.50 | -26.7% | Miss |
| 01 Aug 2024 08:00 | -0.69 | 0.56 | +181.1% | Beat |
| 02 May 2024 08:00 | -0.63 | -0.16 | +74.5% | Beat |
| 15 Feb 2024 08:00 | -0.77 | -0.77 | -0.2% | In line |
| 02 Nov 2023 08:00 | -0.96 | 1.74 | +281.9% | Beat |
| 03 Aug 2023 08:00 | -1.34 | -1.62 | -21.2% | Miss |
| 04 May 2023 08:00 | -1.43 | -1.06 | +25.7% | Beat |
| 23 Feb 2023 08:00 | -1.48 | -1.39 | +6.3% | Beat |
| 27 Oct 2022 08:00 | -1.38 | -1.58 | -14.6% | Miss |
| 28 Jul 2022 08:00 | -1.36 | -2.03 | -49.4% | Miss |
| 28 Apr 2022 08:00 | -1.46 | -1.49 | -2.1% | Miss |
| 10 Feb 2022 08:00 | -1.26 | -1.69 | -34.4% | Miss |
| 28 Oct 2021 08:00 | -1.24 | -1.51 | -21.4% | Miss |
| 03 Aug 2021 08:00 | -1.28 | -1.30 | -1.2% | Miss |
| 29 Apr 2021 08:00 | -1.40 | -1.64 | -17.1% | Miss |
| 11 Feb 2021 08:00 | -1.38 | -1.60 | -15.9% | Miss |
| 05 Nov 2020 08:00 | -1.34 | -1.58 | -18.0% | Miss |
| 06 Aug 2020 08:00 | -1.40 | -1.67 | -19.4% | Miss |
| 06 May 2020 09:00 | -1.51 | -1.52 | -0.9% | In line |
| 06 Feb 2020 08:00 | -1.92 | -1.98 | -3.1% | Miss |
| 31 Oct 2019 08:00 | -1.83 | -1.50 | +18.1% | Beat |
| 06 Aug 2019 07:00 | -1.85 | -1.83 | +1.2% | Beat |
| 01 May 2019 08:00 | -1.80 | -1.42 | +21.1% | Beat |
| 07 Feb 2019 16:00 | -1.93 | -1.82 | +5.7% | Beat |
| 07 Nov 2018 08:00 | -1.79 | -1.56 | +12.9% | Beat |
| 02 Aug 2018 08:00 | -1.71 | -1.83 | -6.9% | Miss |
| 03 May 2018 16:00 | -1.51 | -1.41 | +6.4% | Beat |
| 08 Feb 2018 08:00 | -1.36 | -1.48 | -8.7% | Miss |
| 07 Nov 2017 16:00 | -1.23 | -1.34 | -9.3% | Miss |
| 09 Aug 2017 16:00 | -1.17 | -1.34 | -14.7% | Miss |
| 05 May 2017 08:00 | -1.24 | -1.25 | -0.5% | In line |
| 08 Feb 2017 16:00 | -1.31 | -1.32 | -0.9% | In line |
| 02 Nov 2016 16:00 | -1.16 | -1.21 | -4.0% | Miss |
| 04 Aug 2016 16:00 | -1.27 | -1.05 | +17.4% | Beat |
| 02 May 2016 16:00 | -1.08 | -1.21 | -11.9% | Miss |
| 11 Feb 2016 16:00 | -0.92 | -1.07 | -16.0% | Miss |
| 09 Nov 2015 07:00 | -0.90 | -0.91 | -1.5% | Miss |
| 06 Aug 2015 16:00 | -0.73 | -0.85 | -16.8% | Miss |
| 07 May 2015 16:00 | -0.60 | -0.62 | -2.7% | Miss |
| 12 Feb 2015 16:00 | -0.57 | -0.28 | +50.9% | Beat |
| 05 Nov 2014 16:00 | -0.64 | -0.58 | +9.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 3.7B | +65.2% | 313.7M | 8.4% | 2.33 | +206.9% | 465.4M |
| 2024 | 2.2B | +23.0% | -278.2M | -12.4% | -2.18 | +38.1% | -42.6M |
| 2023 | 1.8B | +76.2% | -440.2M | -24.1% | -3.52 | +62.2% | 41.9M |
| 2022 | 1B | — | -1.1B | -109.0% | -9.30 | — | -613.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 05 Apr 2024 | 150.15 | 154.00 | 149.41 | 153.56 | +1.37% | 351,500 | |
| 04 Apr 2024 | 151.00 | 154.38 | 150.80 | 151.48 | +0.43% | 531,900 | |
| 03 Apr 2024 | 150.19 | 151.27 | 149.25 | 150.83 | -0.14% | 315,100 | |
| 02 Apr 2024 | 151.89 | 152.27 | 150.67 | 151.04 | -1.49% | 445,600 | |
| 01 Apr 2024 | 148.57 | 154.21 | 147.58 | 153.33 | +2.60% | 523,300 | |
| 28 Mar 2024 | 154.48 | 154.50 | 149.32 | 149.45 | -3.20% | 666,600 | |
| 27 Mar 2024 | 152.83 | 155.28 | 150.40 | 154.39 | +1.59% | 463,000 | |
| 26 Mar 2024 | 152.51 | 153.43 | 150.81 | 151.97 | -0.07% | 532,500 | |
| 25 Mar 2024 | 147.15 | 152.63 | 146.43 | 152.07 | +3.79% | 799,300 | |
| 22 Mar 2024 | 146.65 | 147.10 | 143.66 | 146.51 | -0.08% | 834,200 | |
| 21 Mar 2024 | 149.70 | 150.68 | 145.41 | 146.62 | -0.93% | 611,500 | |
| 20 Mar 2024 | 148.00 | 148.64 | 145.22 | 147.99 | -0.12% | 439,800 | |
| 19 Mar 2024 | 146.93 | 149.69 | 146.00 | 148.17 | +0.52% | 517,200 | |
| 18 Mar 2024 | 150.68 | 151.00 | 147.18 | 147.41 | -1.25% | 460,700 | |
| 15 Mar 2024 | 148.50 | 150.09 | 145.54 | 149.27 | +0.50% | 906,200 | |
| 14 Mar 2024 | 147.68 | 149.59 | 145.77 | 148.53 | +0.07% | 505,800 | |
| 13 Mar 2024 | 146.82 | 151.47 | 146.82 | 148.42 | +1.21% | 859,000 | |
| 12 Mar 2024 | 150.02 | 150.02 | 146.61 | 146.65 | -1.64% | 683,600 | |
| 11 Mar 2024 | 150.24 | 152.50 | 148.88 | 149.10 | -0.48% | 662,000 | |
| 08 Mar 2024 | 150.96 | 152.88 | 149.14 | 149.82 | -0.03% | 637,600 | |
| 07 Mar 2024 | 150.42 | 150.68 | 149.23 | 149.86 | +0.13% | 563,900 | |
| 06 Mar 2024 | 150.15 | 150.24 | 147.63 | 149.66 | -0.01% | 521,500 | |
| 05 Mar 2024 | 148.94 | 151.21 | 147.52 | 149.68 | -0.24% | 703,400 | |
| 04 Mar 2024 | 153.16 | 154.85 | 149.89 | 150.04 | -1.68% | 991,900 | |
| 01 Mar 2024 | 150.90 | 155.91 | 150.00 | 152.61 | +1.01% | 538,900 |
Page 27 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down (opens in a new tab) BioPharma Dive · 06 Nov 2026 13:13
- Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership (opens in a new tab) 04 Nov 2026 22:15
- Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference (opens in a new tab) 04 Nov 2026 13:00
- What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change? (opens in a new tab) Simply Wall St. · 04 Nov 2026 01:08
- Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026 (opens in a new tab) 03 Nov 2026 13:30
- Alnylam Pharmaceuticals To Present New Helios-B Clinical Data At American Heart Association Scientific Sessions 2026 (opens in a new tab) Benzinga · 03 Nov 2026 09:33
- Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380 (opens in a new tab) Benzinga · 02 Nov 2026 16:06
- Should You Buy The Dip In Alnylam Stock? (opens in a new tab) Trefis · 02 Nov 2026 14:39
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience (opens in a new tab) BioPharma Dive · 02 Nov 2026 14:00
- Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225 (opens in a new tab) Benzinga · 02 Nov 2026 11:38
- FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight (opens in a new tab) Stocktwits · 02 Nov 2026 10:36
- Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323 (opens in a new tab) Benzinga · 02 Nov 2026 08:41
- Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales Concerns (opens in a new tab) Simply Wall St. · 31 Oct 2026 04:21
- Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow (opens in a new tab) SeekingAlpha · 30 Oct 2026 19:30
- Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says (opens in a new tab) MT Newswires · 30 Oct 2026 17:00
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 156.66 USD
- Market cap
- 21.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 12.2 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 9.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Thin interest cover: operating profit is only 2.0× the interest
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 7.88× | Good | 31.09× |
| P/E (forward) | 13.98× | Good | 14.98× |
| Price / book | 5.79× | Weak | 3.87× |
| Price / sales | 4.17× | Fair | 3.42× |
| EV / EBITDA | 19.74× | Weak | 13.09× |
| Free cash flow yield | 1.6% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 77.3% | Good | 59.2% |
| Operating margin | 23.7% | Good | 7.8% |
| Net margin | 52.8% | Good | 3.4% |
| Return on equity | 138.1% | Good | 5.7% |
| Return on assets | 9.5% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 53% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.83× | Fair | 0.46× |
| Net debt / EBITDA | -0.57× | Good | 1.48× |
| Interest cover | 1.99× | Weak | 3.26× |
| Current ratio | 2.48× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ALNY and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.